Home›Stock Screener›Vimta Labs›Quarterly Results

Vimta Labs Quarterly Results

Latest Quarter Net Profit
₹15 Cr
QSept 2024
Quarterly Results

Vimta Labs quarterly results. In Sept 2024, Vimta Labs (VIMTALABS) reported revenue ₹85 Cr and net profit ₹15 Cr — revenue +25.0% YoY. View VIMTALABS 52-week performance for the annual high/low range and current price position.

VIMTALABS Quarterly Results — Revenue, Profit & EPS Highlights

Vimta Labs latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit VIMTALABS screener.

  • Revenue of ₹85 Cr in Sept 2024 (+6.2% vs Mar 2024, +25.0% vs Sept 2023)
  • Net Profit of ₹15 Cr in Sept 2024 (+25.0% vs Mar 2024, +150.0% vs Sept 2023)
  • EBITDA of ₹29 Cr in Sept 2024 (+16.0% vs Mar 2024)
  • Operating Margin of 33.0% in Sept 2024 (+2.0pp vs Mar 2024)
  • Earnings Per Share of ₹6.88 in Sept 2024 (+23.3% vs Mar 2024)

Vimta Labs Quarterly Results — Revenue, EBITDA, Net Profit & EPS

VIMTALABS quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2024 Mar 2024 Jun 2024 Dec 2024 Sept 2023 QoQ YoY
Revenue (₹ Cr) 85 80 76 95 68 6.3% 25.0%
Net Profit (₹ Cr) 15 12 12 22 6 - -
EBITDA (₹ Cr) 29 25 25 38 18 - -
EPS (₹) 6.88 5.58 5.54 9.65 2.86 - -
Operating Margin (%) 33.0% 31.0% 32.0% 37.0% 24.0% - -

VIMTALABS Share Price Trend — 1-Year Movement Across Quarterly Results

Vimta Labs 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore VIMTALABS price movement history to track price trends across different timeframes.

Profitability Ratios

Profit Margin 17.6%
EBITDA Margin 34.1%
Operating Margin 33.0%
ROE (Annual) 18.8%

Balance Sheet Highlights

Total Assets ₹400 Cr
Total Equity ₹320 Cr
Current Assets ₹ Cr
Current Liabilities ₹26 Cr

Cash Flow Analysis

Operating Cash Flow ₹61 Cr
Investing Cash Flow ₹-76 Cr
Financing Cash Flow ₹-2 Cr
Net Cash Flow ₹-17 Cr

Current Market Data

Current Price ₹471.95
Exchange NSE
Last Updated Nov 19, 2026

VIMTALABS vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Vimta Labs latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Sept 2026
₹451,074.97 Cr 1900.0 16,617 1,995 +10.6% - 12.0% 228.9
Divis Laboratories
Sept 2026
₹294,139.19 Cr 11178.0 3,770 1,127 +26.3% - 29.9% 263.1
Torrent Pharmaceuti…
Mar 2026
₹188,719.51 Cr 4611.0 4,111 364 +27.7% +42.2% 8.9% 400.6
Apollo Hospitals
Sept 2026
₹126,832.45 Cr 8738.0 7,673 660 +15.2% - 8.6% 199.4
Laurus Labs
Sept 2026
₹125,946.78 Cr 2306.0 2,219 436 +21.7% - 19.6% 282.3
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data

QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores